# Dupilumab

## Dupixent inj 300mg/2mL

##### 

| 藥品代碼   | IDUPI                                                                                                                                                                                                                                                                                                                                                                 |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.                                                                                                                                                                                                                            |
| 用法用量   | DUPIXENT is administered by subcutaneous injection. The recommended dose of DUPIXENT for adult patients is an initial dose of 600 mg (two 300 mg injections)， followed by 300 mg given every other week.                                                                                                                                                             |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                          |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                          |
| 禁忌       | Known hypersensitivity to dupilumab or any component of the formulation                                                                                                                                                                                                                                                                                               |
| 副作用     | >10%: Local: Injection site reaction (10% to 18%) 1% to 10%: Gastrointestinal: Oral herpes simplex infection (4%) Hematologic & oncologic: Eosinophilia (<2%) Immunologic: Antibody development (6% to 9%; neutralizing: 2% to 4%) Infection: Herpes simplex infection (2%) Ophthalmic: Conjunctivitis (10%)， eye pruritus (1%) Respiratory: Oropharyngeal pain (2%) |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | Unknown 沒有資料                                                                                                                                                                                                                                                                                                                                                      |

